Incruse Ellipta (previously Incruse)

RSS

umeclidinium bromide

Authorised
This medicine is authorised for use in the European Union.

Overview

Incruse Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Incruse Ellipta is used for maintenance (regular) treatment.

Incruse Ellipta contains the active substance umeclidinium bromide.

This EPAR was last updated on 15/11/2022

Authorisation details

Product details
Name
Incruse Ellipta (previously Incruse)
Agency product number
EMEA/H/C/002809
Active substance
umeclidinium bromide
International non-proprietary name (INN) or common name
umeclidinium bromide
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
R03BB07
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
GlaxoSmithKline (Ireland) Limited
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
28/04/2014
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland

Product information

09/11/2022 Incruse Ellipta (previously Incruse) - EMEA/H/C/002809 - PSUSA/00010263/202112

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Assessment history

How useful was this page?

Add your rating